Pyrazole compounds and uses thereof

A method of treating a malignant condition in a subject in need thereof, comprising administering to the subject a compound having Formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof:

• wherein:
• R1 and R2 are each independently selected from H;
• and straight or branched C1-C8 alkyl, straight or branched C1-C5 alkoxy, —C(O)-(straight or branched C1-C5 alkyl), phenyl, naphthyl, anthracenyl, and C3-C7 heteroaryl, each optionally substituted by at least one of halide, hydroxyl, —C(O)OR10, —OC(O)R10, —R13OR14′, —OR15′, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, —C(O)NR11R12′, and —NR11C(O)R12′;
• or
• R1 and R2 together with the nitrogen atom they are connected to form a 4-7 membered saturated, unsaturated, or aromatic ring that optionally comprises at least one of N, O, NH, C═O, and SO2, and is optionally substituted with at least one of straight or branched C1-C5 alkyl, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, hydroxyl, halide, and cyano;
• R3 and R4 are each independently selected from H, and straight or branched C1-C8 alkyl optionally substituted by at least one of halide, hydroxyl, C1-C5 alkoxy, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, —C(O)OR10, —OC(O)R10, —C(O)NR11R12′, and —NR11C(O)R12′;
• or
• R1 or R2 together with R3 and the carbon and nitrogen atoms they are each connected to form a 4-7 membered saturated, unsaturated, or aromatic ring that optionally comprises at least one of N, NH, O, C═O, and SO2, and is optionally substituted with at least one of straight or branched C1-C5 alkyl, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, hydroxyl, and halide;
• W, X, Y, and Z are each selected from CH, CR5, CR5c, NH, N, and S;
• provided that at least one of W, X, Y and Z is selected from NH, N, and S;
• and provided that, when W is N and Z is N, then X is CR5c;
• n is an integer of 0 or 1;
• R5 is OH, NH2, or halide;
• R5c is OH or NH2;
• R8 is selected from H and halide;
• and straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, and straight or branched C2-C8 alkynyl, each optionally substituted by at least one halide;
• R6 is selected from straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, straight or branched C2-C8 alkynyl, C5-C10 cycloalkyl, and saturated or unsaturated 4-6 membered heterocyclyl, each optionally substituted by at least one of straight or branched C1-C8 alkyl, C3-C7 cycloalkyl, 4-6 membered heterocyclyl, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, halide, hydroxyl, and C1-C5 haloalkyl;
• R7 is selected from straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, and straight or branched C2-C8 alkynyl, each independently substituted by at least one of C3-C7 cycloalkyl, 4-6 membered heterocyclyl, phenyl, naphthyl, anthracenyl, C3-C7 heteroaryl, halide, hydroxyl, and C1-C5 haloalkyl;
• each R10 is independently straight or branched C1-C8 alkyl;
• each R11 and R12′ is independently H, or straight or branched C1-C8 alkyl;
• each R13 is independently straight or branched C1-C8 alkylene;
• and
• each R14′ and R15′ is independently H, or straight or branched C1-C8 alkyl;
• wherein each heteroaryl independently comprises at least one heteroatom selected from N, O, and S and each heterocyclyl independently comprises at least one heteroatom selected from N, O, and S, and
• wherein the malignant condition is selected from multiple myeloma, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), melanoma, breast cancer, diffuse large B cell lymphoma (DLBCL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), prostate cancer, colorectal cancer, and head and neck cancer.